1xbet모바일 Pharmaceutical Co., Ltd.

Tokyo, Japan - September 5, 2013 - 1xbet모바일 Pharmaceutical Co., Ltd. is pleased to announce an agreement with Astex Pharmaceuticals, Inc. ("Astex") to acquire Astex via an all-cash tender offer. The total purchase price of 6 million is based on the treasury stock calculation method and a tender offer of US .50 per share for all outstanding common shares.

Objectives of the Acquisition

1xbet모바일 aims to enhance its discovery and development of drugs with novel working mechanisms by combining Astex's fragment-based drug discovery technology with 1xbet모바일's own R&D strengths in areas such as central nervous system diseases. The fragment-based discovery technology, named PYRAMID™, is one of the most significant new drug discovery platforms of the past two decades and holds significant promise to bring new therapies more quickly to awaiting patients and physicians. 1xbet모바일 will also strengthen its promising oncology development portfolio and inline oncology offerings.

Dr. Taro Iwamoto, 1xbet모바일 Pharmaceutical's President and Representative Director, remarked, "I hope that this acquisition of Astex will strengthen not only our cancer portfolio but also our drug discovery research in the central nervous system field, through the acquisition of Astex's fragment-based drug design technology. Astex's unique fragment-based drug discovery technology and clinical oncology research and development capabilities, born out of the passion of its researchers, exemplify our corporate mottos and belief in "Sozosei (Creativity) and Jissho (Proof through Execution). I would like 1xbet모바일 Pharmaceutical to continue to respect Astex's uniqueness and leverage it to bring further growth for 1xbet모바일 Pharmaceutical."

About 1xbet모바일 Pharmaceuticals, Inc.

Astex is a bio-venture 1xbet모바일mpany established in 1991, with a fragment-based drug dis1xbet모바일very research center in Cambridge, England and a clinical research and development function in California. Fragment-based dis1xbet모바일very technology enables more rapid dis1xbet모바일very and development of 1xbet모바일mpounds for target proteins implicated in diseases than has heretofore been possible with high-throughout screening. Simply described, this technology evaluates binding of target proteins with small molecules via 3D structural analysis. As a result, in the past 8 years Astex has advanced 8 new 1xbet모바일mpounds to the clinical R&D stage in the fields of on1xbet모바일logy and the central nervous system. Four of these are in phase-2 clinical trials, including SGI-110 a novel DNA methylation inhibitor and AT13387, an inhibitor of heat shock protein 90 (HSP90) which are involved in the reproduction of cancer cells, and four are in phase-1 trials. Four of these 1xbet모바일mpounds are undergoing clinical trials in several partnerships.

Astex achieved the development and launch of Da1xbet모바일gen^®, a drug that treats myelodysplastic syndromes and elderly acute myeloid leukemia. Da1xbet모바일gen^®(decitabine) has worldwide sales of approximately 0 million and is presently sold by Eisai Inc. in North America and by Janssen in other regions.